Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man.
Saghari M, Gal P, Ziagkos D, Burggraaf J, Powell JF, Brennan N, Rissmann R, van Doorn MBA, Moerland M. Saghari M, et al. Among authors: van doorn mba. Br J Clin Pharmacol. 2021 Apr;87(4):1953-1962. doi: 10.1111/bcp.14588. Epub 2020 Oct 28. Br J Clin Pharmacol. 2021. PMID: 33025648 Free PMC article. Clinical Trial.
Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.
van Doorn M, Kemme M, Ouwens M, van Hoogdalem EJ, Jones R, Romijn H, de Kam M, Schoemaker R, Burggraaf K, Cohen A. van Doorn M, et al. Br J Clin Pharmacol. 2006 Oct;62(4):391-402. doi: 10.1111/j.1365-2125.2005.02532.x. Br J Clin Pharmacol. 2006. PMID: 16995860 Free PMC article. Clinical Trial.
Injection site reactions after subcutaneous oligonucleotide therapy.
van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, Rissmann R, Burggraaf J. van Meer L, et al. Br J Clin Pharmacol. 2016 Aug;82(2):340-51. doi: 10.1111/bcp.12961. Epub 2016 May 31. Br J Clin Pharmacol. 2016. PMID: 27061947 Free PMC article. Review.
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J, Rissmann R. Balak DM, et al. Clin Immunol. 2017 Jan;174:63-72. doi: 10.1016/j.clim.2016.09.015. Epub 2016 Nov 20. Clin Immunol. 2017. PMID: 27876460 Clinical Trial.
Complement Activation in Inflammatory Skin Diseases.
Giang J, Seelen MAJ, van Doorn MBA, Rissmann R, Prens EP, Damman J. Giang J, et al. Among authors: van doorn mba. Front Immunol. 2018 Apr 16;9:639. doi: 10.3389/fimmu.2018.00639. eCollection 2018. Front Immunol. 2018. PMID: 29713318 Free PMC article. Review.
Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.
van der Kolk T, Assil S, Rijneveld R, Klaassen ES, Feiss G, Florencia E, Prens EP, Burggraaf J, Moerland M, Rissmann R, van Doorn MBA. van der Kolk T, et al. Among authors: van doorn mba. Clin Transl Sci. 2018 Nov;11(6):607-615. doi: 10.1111/cts.12563. Epub 2018 Jul 3. Clin Transl Sci. 2018. PMID: 29768709 Free PMC article. Clinical Trial.
113 results